GlaxoSmithKline Pharmaceuticals Limited Stock Price Today (NSE: GLAXO)

GlaxoSmithKline Pharmaceuticals Limited

2856.20+37.30 (+1.32%)
Market Closed

Fundamental Score

...

GlaxoSmithKline Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

GlaxoSmithKline Pharmaceuticals Limited share price today is 2856.20, up +1.32% on NSE/BSE as of 16 September 2026. GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 48.39K (Cr). The 52-week high for GLAXO share price is 3120.70 and the 52-week low is 2088.10. At a P/E ratio of 46.06x, GLAXO is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 49.11% and a debt-to-equity ratio of 0.00.

GlaxoSmithKline Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
3120.70
Low
2576.10
Volume
1.8L
Change
+12.58%

GlaxoSmithKline Pharmaceuticals Limited share price chart: 12.58% return over the past month. 52-week high ₹3120.70, 52-week low ₹2088.10.

GlaxoSmithKline Pharmaceuticals Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
2818.002878.002755.902856.2085.46K (Cr)
2814.902840.802775.802818.9039.81K (Cr)
2840.902863.502793.902828.4038.43K (Cr)
2934.802961.802832.202840.9038.56K (Cr)
2928.202959.602875.002890.2029.12K (Cr)
2978.003001.302921.202928.2050.68K (Cr)
2937.903075.002932.702957.801.56L (Cr)
2938.902972.802925.502958.1048.11K (Cr)
2962.402998.002930.402937.5056.01K (Cr)
2972.602990.102908.502949.9059.23K (Cr)

GlaxoSmithKline Pharmaceuticals Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
3040.003075.002755.902856.20-6.05%
2665.403120.702515.003050.10+14.43%
2476.802679.002370.002655.40+7.21%
2200.002460.902088.102450.30+11.38%
2342.002520.002194.402210.20-5.63%
2305.002529.902261.902336.40+1.36%
2520.002581.602217.602283.00-9.40%
2400.202719.802342.102571.60+7.14%
2476.002528.002220.302401.60-3.00%
2551.002635.002362.602473.60-3.03%
2644.002694.002404.202569.50-2.82%
2659.702795.902601.002618.60-1.55%

Returns & Performance

Excellent

Return on Equity (ROE)

49.11%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

59.34%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

29.10%

Average operating profit margin over 5 years

Good

Dividend Yield

2.29%

Annual dividend as % of current share price

GlaxoSmithKline Pharmaceuticals Limited Valuation Check

Poor

Price to Earnings (P/E)

46.06x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

75.00%

% shares held by company founders/management

Poor

FII Holding

4.79%

% shares held by foreign institutional investors

Average

DII Holding

7.81%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

5.70%

Net profit growth vs same quarter last year

Good

Revenue Growth (Quarterly YoY)

16.55%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

3.62%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

20.86%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

23.67%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

516.02x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

3.88K (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

GlaxoSmithKline Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GLAXO across key market metrics for learning purposes.

Positive Indicators

12 factors identified

Strong Return on Equity (49.11%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (59.34%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (29.10%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Strong Revenue Growth (16.55%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Excellent EPS Growth (20.86% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (23.67% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (516.02x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 1.79)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹3880.28 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (75.00%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Premium Valuation Risk (P/E: 46.06x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

High Price-to-Book Ratio (24.80x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Limited Growth History (3.62% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

GlaxoSmithKline Pharmaceuticals Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare GlaxoSmithKline Pharmaceuticals Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
56/100
2856
₹48386.88
46.1
Average
49.11%
Excellent
59.34%
Excellent
0.0
Excellent
23.67%
Excellent
3.62%
Average
2.29%
66.4/100
1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9468
₹250888.75
85.9
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4940
₹167182.32
78.9
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1372
₹110828.94
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1941
₹104867.93
95.8
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1683
₹96839.82
26.3
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2101
₹96054.51
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95565.75
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2294
₹94729.81
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

GlaxoSmithKline Pharmaceuticals Limited PE Ratio History

Historical price-to-earnings ratio for GLAXO — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202554.76₹2473.6045.2x
FY 202434.83₹2251.8564.7x
FY 202336.05₹1898.1552.7x
FY 2022100.04₹1318.7513.2x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

GlaxoSmithKline Pharmaceuticals Limited Dividend History

Annual cash dividends paid by GLAXO — dividend yield 2.29%

Financial YearDividends Paid (₹ Cr)
FY 2025749.38 Cr
FY 2024541.57 Cr
FY 20231525.50 Cr
FY 2022506.63 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

GlaxoSmithKline Pharmaceuticals Limited Quarterly Performance

Latest quarterly metrics for GLAXO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

16.55%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

5.70%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

3.62%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

23.67%

Compounded annual net profit growth over 5 years

GlaxoSmithKline Pharmaceuticals Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GLAXO — calculated from daily price history

41RSI 14
Neutral — RSI 41

Momentum is balanced — neither overbought nor oversold.

SMA 50
2677
▲ Price above SMA 50 — Short-term bullish
SMA 200
2485
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
152K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

GlaxoSmithKline Pharmaceuticals Limited Financial Statements

Annual income statement, balance sheet and cash flow for GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for GlaxoSmithKline Pharmaceuticals Limited

Loading latest quarterly results...

About GLAXO (GlaxoSmithKline Pharmaceuticals Limited)

GlaxoSmithKline Pharmaceuticals Ltd is a global healthcare powerhouse dedicated to the discovery, development, and manufacturing of innovative medicines and vaccines. With a legacy... spanning centuries, GSK focuses on addressing some of the world's most significant health challenges, ranging from infectious diseases and respiratory ailments to cancer and immune-related disorders. The company invests heavily in research and development, fostering a culture of scientific excellence and collaboration to accelerate the delivery of life-changing therapies. GSK's commitment extends beyond scientific innovation; it encompasses a deep-rooted dedication to ethical practices, sustainability, and improving global health equity. Through strategic partnerships and global initiatives, GSK strives to ensure that its medicines and vaccines reach those who need them most, regardless of geography or socioeconomic status. GSK's diverse product portfolio encompasses a wide range of therapeutic areas, offering solutions for prevention, treatment, and management of various medical conditions. Its vaccine division plays a crucial role in protecting individuals and communities from preventable diseases, with a strong emphasis on pediatric and adolescent immunization. From groundbreaking oncology drugs targeting specific cancer pathways to novel respiratory therapies designed to alleviate breathing difficulties, GSK's pharmaceuticals are making a tangible difference in the lives of patients worldwide. The company's commitment to innovation extends to its manufacturing processes, leveraging advanced technologies to optimize production efficiency and ensure the highest quality standards. Beyond its core business activities, GSK actively engages in corporate social responsibility initiatives, supporting programs that promote health education, access to healthcare, and community development. The company is dedicated to reducing its environmental impact and operates under stringent ethical guidelines to ensure transparency and accountability in all its operations. GSK recognizes that its success is intrinsically linked to the well-being of the communities it serves and strives to be a responsible corporate citizen, contributing to a healthier and more sustainable future. The firm’s focus is on developing and commercializing cutting-edge pharmaceutical products, which contributes to better patient outcomes.

Company Details

Symbol:GLAXO
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Bhushan Akshikar
MD & Executive Director
Mr. Juby Chandy
Whole-Time Director & CFO
Ms. Aparajita Rajput
Vice President of Technology

GLAXO Share Price: Frequently Asked Questions

What is the current share price of GlaxoSmithKline Pharmaceuticals Limited?

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) trades at ₹2856.20 on NSE and BSE. Market cap ₹48.39K (Cr). Educational data only.

What is the P/E ratio of GlaxoSmithKline Pharmaceuticals Limited?

GlaxoSmithKline Pharmaceuticals Limited has a P/E of 46.06x vs industry average 34.89x.

What is the Bull Run score for GlaxoSmithKline Pharmaceuticals Limited?

GlaxoSmithKline Pharmaceuticals Limited has a Bull Run score of 56/100 based on 25+ financial parameters.

Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?

GlaxoSmithKline Pharmaceuticals Limited has a dividend yield of 2.29%. Past dividends don't guarantee future payments.

What is the ROE of GlaxoSmithKline Pharmaceuticals Limited?

GlaxoSmithKline Pharmaceuticals Limited has ROE of 49.11%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of GlaxoSmithKline Pharmaceuticals Limited?

GlaxoSmithKline Pharmaceuticals Limited has debt-to-equity of 0.00.

Is GlaxoSmithKline Pharmaceuticals Limited a good investment?

Bull Run gives GlaxoSmithKline Pharmaceuticals Limited a score of 56/100. This is not investment advice — consult a SEBI-registered advisor.